Last reviewed · How we verify
Part 2: Pump Spray
At a glance
| Generic name | Part 2: Pump Spray |
|---|---|
| Also known as | Avobenzone, Homosalate, Octisalate, Octinoxate |
| Sponsor | Food and Drug Administration (FDA) |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Contribution of Nasal IgE Production to the Boost of Systemic Allergen-specific IgE Upon Nasal Allergen Contact (NA)
- Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of QAU145 in Patients With Cystic Fibrosis (PHASE2)
- Study to Determine the Single and Repeat Dose Pharmacokinetics, Food Effect, Proton Pump Inhibitor (PPI) Drug Interaction, Safety and Tolerability of Oral Prototype Formulations of BOS172767 in Healthy Subjects (PHASE1)
- A Study to Evaluate the Safety, Tolerability Pharmacokinetics, and Pharmacodynamics of a New Spray Dried Dispersion (SDD) Formulation of CC-11050 After Single Dose of CC-11050 and to Evaluate the Pharmacokinetics of CC-11050 Under Fasted and Fed Conditions and After Coadministration With Omeprazole (PHASE1)
- Assessment of the Human Systemic Absorption of Sunscreen Ingredients (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Part 2: Pump Spray CI brief — competitive landscape report
- Part 2: Pump Spray updates RSS · CI watch RSS
- Food and Drug Administration (FDA) portfolio CI